Navigation Links
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Date:10/15/2007

ANN ARBOR, Mich., Oct. 15 /PRNewswire/ -- Velcura Therapeutics, Inc. has named Jeffrey N. Fellows, a biotechnology regulatory executive with more than 20 years of successful regulatory experience, as Vice President of Regulatory Affairs.

Velcura Therapeutics President and CEO Michael W. Long, PhD, said, "Jeff is a great addition to our senior management team. He will be responsible for our clinical trials applications, regulatory compliance and interactions with the Federal Drug Administration. His more than two decades of experience will be critical in helping Velcura navigate the regulatory path for VEL-0230, our new drug that stimulates bone formation and inhibits bone loss." Dr. Long added, "Jeff's past experience with the Oncology Division at FDA is a definite plus as our initial clinical trial of VEL-0230 in patients will be for treatment for Multiple Myeloma Bone Disease, a blood cancer associated with profound bone loss."

Immediately before joining Velcura Therapeutics, Fellows was Vice President of Regulatory Affairs for Cell Therapeutics, Inc. in Seattle, where for the past three years he was the main liaison with the FDA and responsible for the development of global regulatory strategy and agency filings for the oncology focused company.

Prior to CTI, Fellows worked for Amgen Inc. in Thousand Oaks, CA, and worked in a series of increasingly responsible positions, eventually serving as Director of Regulatory Affairs and Global Regulatory Team Leader in Thousand Oaks, California. There Fellows served on Corporate Global Product Strategy Teams for early- and late-stage development compounds and led Global Regulatory Teams in the United States, Europe, Canada, Australia, and Japan.

After graduation from Oregon State University with a Bachelor of Science in Microbiology, Fellows began his career in regulatory affairs at NeoRx Corporation, where he prepared Investigational New Drug Applications for anti- cancer products. He worked for Synergen, Inc. in Boulder, Colorado, from 1990 until Amgen purchased Synergen in late 1994.

Jeffery Fellows lives in Woodway, Washington, and will work from Velcura's Seattle office.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics, Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... a free AFM Luncheon for all SPIE attendees and Park ... CA, just one block from the San Jose Convention Center. The luncheon will ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
Breaking Biology News(10 mins):